Medication nonadherence is a significant cause of relapse in patients with schizophrenia, and is often precipitated by medication side effects. This presentation will summarize the data on side-effects and long-term impacts of antipsychotic nonadherence in schizophrenia, examine the advantages of Long Acting Injectable (LAI) antipsychotics for adherence and improved outcomes, and describe new and emerging oral antipsychotics that can be used for treating schizophrenia. It will also identify gender, racial, and socioeconomic disparities that affect schizophrenia diagnosis and care.
